Literature DB >> 32688386

Catheter-related bloodstream infections: predictive factors for Gram-negative bacteria aetiology and 30 day mortality in a multicentre prospective cohort.

Federica Calò1, Pilar Retamar2, Pedro María Martínez Pérez-Crespo2, Joaquín Lanz-García2, Adrian Sousa3, Josune Goikoetxea4, José María Reguera-Iglesias5, Eva León6, Carlos Armiñanzas7, Maria Angeles Mantecón8, Jesús Rodríguez-Baño2, Luis Eduardo López-Cortés2.   

Abstract

BACKGROUND: Catheter-related bloodstream infections (CRBSIs) increase morbidity and mortality, prolong hospitalization and generate considerable medical costs. Recent guidelines for CRBSI recommend empirical therapy against Gram-positive bacteria (GPB) and restrict coverage for Gram-negative bacteria (GNB) only to specific circumstances.
OBJECTIVES: To investigate predictors of GNB aetiology in CRBSI and to assess the predictors of outcome in patients with CRBSI.
METHODS: Patients with CRBSI were selected from the PROBAC cohort, a prospective, observational, multicentre national cohort study including patients with bloodstream infections consecutively admitted to 26 Spanish hospitals in a 6 month period (October 2016-March 2017). Outcome variables were GNB aetiology and 30 day mortality. Adjusted analyses were performed by logistic regression.
RESULTS: Six hundred and thirty-one episodes of CRBSI were included in the study. Risk factors independently related to GNB aetiology were central venous catheter (CVC) [OR 1.60 (95% CI: 1.05-2.44), P = 0.028], sepsis/septic shock [OR: 1.76 (95% CI: 1.11-2.80), P = 0.016], antibiotic therapy in the previous 30 days [OR: 1.56 (95% CI: 1.02-2.36), P = 0.037], neutropenia <500/μL [OR: 2.01 (95% CI: 1.04-3.87), P = 0.037] and peripheral vascular disease [OR: 2.04 (95% CI: 1.13-3.68), P = 0.018]. GNB were not associated with increased mortality in adjusted analysis, while removal of catheter [OR: 0.24 (95% CI: 0.09-0.61), P = 0.002] and adequate empirical treatment [OR: 0.37 (95% CI: 0.18-0.77), P = 0.008] were strong protective factors.
CONCLUSIONS: Our study reinforces the recommendation that empirical coverage should cover GNB in patients presenting with sepsis/septic shock and in neutropenic patients. Catheter removal and adequate empirical treatment were both protective factors against mortality in patients with CRBSI.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2020        PMID: 32688386     DOI: 10.1093/jac/dkaa262

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

1.  Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project.

Authors:  Marco Mussa; Pedro María Martínez Pérez-Crespo; Luis Eduardo Lopez-Cortes; Pilar Retamar-Gentil; Adrián Sousa-Dominguez; Ane Josune Goikoetxea-Aguirre; José María Reguera-Iglesias; Eva León Jiménez; Isabel Fernández-Natal; Carlos Armiñanzas-Castillo; Lucía Boix-Palop; Jordi Cuquet-Pedragosa; Miguel Ángel Morán Rodríguez; Jonathan Fernandez-Suarez; Alfonso Del Arco-Jiménez; Alfredo Jóver-Saenz; Alberto Bahamonde-Carrasco; Fátima Galan-Sanchez; Juan Manuel Sánchez-Calvo; Alejandro Smithson-Amat; David Vinuesa-García; Antonio Sánchez-Porto; Inmaculada López-Hernández; Jesús Rodríguez-Baño
Journal:  Microbiol Spectr       Date:  2022-06-30

2.  Development and validation of a multivariable prediction model of central venous catheter-tip colonization in a cohort of five randomized trials.

Authors:  Jeanne Iachkine; Niccolò Buetti; Harm-Jan de Grooth; Anaïs R Briant; Olivier Mimoz; Bruno Mégarbane; Jean-Paul Mira; Stéphane Ruckly; Bertrand Souweine; Damien du Cheyron; Leonard A Mermel; Jean-François Timsit; Jean-Jacques Parienti
Journal:  Crit Care       Date:  2022-07-07       Impact factor: 19.334

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.